Seeking Alpha

Alnylam Pharmaceuticals (ALNY) announces a restructuring plan that will include a 33% reduction...

Alnylam Pharmaceuticals (ALNY) announces a restructuring plan that will include a 33% reduction in the size of its workforce, with the goal of focusing on drugs aimed at treating amyloidosis and hemophilia. Analysts estimate Alnylam's 2011 revenue fell 17%, and expect its 2012 revenue to decline another 26.3%. Shares are currently halted.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|